FDA Approval of Capivasertib for Advanced Prostate Cancer: What Patients Should Know

The U.S. Food and Drug Administration (FDA) has not granted approval for the combination of capivasertib with abiraterone and prednisone for the treatment of prostate cancer. While capivasertib (Truqap) is an FDA-approved therapy for certain types of breast cancer, its use in prostate cancer remains under clinical investigation. Patients and caregivers should consult with their oncologists regarding current, evidence-based treatment options for metastatic castration-resistant prostate cancer (mCRPC).

Current Regulatory Status of Capivasertib

As of May 2024, the FDA has not cleared capivasertib for use in prostate cancer patients, including those with PTEN-deficient tumors. The drug is currently indicated by the FDA solely for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. This approval is specifically for patients who possess one or more PIK3CA, AKT1, or PTEN alterations, following progression on at least one endocrine-based regimen.

Why PTEN Deficiency Matters in Prostate Cancer

PTEN (phosphatase and tensin homolog) is a tumor suppressor gene that frequently undergoes mutation or deletion in prostate cancer. According to the National Cancer Institute, the loss of PTEN function leads to the overactivation of the PI3K/AKT signaling pathway, which promotes tumor cell survival and growth. Researchers are actively studying AKT inhibitors like capivasertib to determine if blocking this pathway can effectively slow or stop disease progression in patients whose tumors harbor these specific genomic alterations.

Ongoing Clinical Research

The interest in capivasertib for prostate cancer stems from the CAPItello-276 clinical trial. This Phase 3 study was designed to evaluate the efficacy of capivasertib in combination with docetaxel in patients with mCRPC. Data from ongoing trials are essential for the FDA to determine whether the benefits of the drug—such as improved progression-free survival—outweigh the risks of side effects, which commonly include diarrhea, rash, and hyperglycemia.

Established Treatments for Metastatic Prostate Cancer

For patients facing metastatic castration-resistant prostate cancer, the current standard of care often involves therapies that have already received regulatory approval based on demonstrated survival benefits. These include:

• Androgen Receptor Signaling Inhibitors: Medications such as abiraterone (Zytiga) and enzalutamide (Xtandi).
• Taxane Chemotherapy: Agents such as docetaxel and cabazitaxel.
• PARP Inhibitors: Targeted therapies like olaparib (Lynparza) or rucaparib (Rubraca) for patients with specific BRCA or other homologous recombination repair (HRR) gene mutations.
• Radioligand Therapy: Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for patients with PSMA-positive mCRPC.

Frequently Asked Questions

Can I access capivasertib through a clinical trial?

Patients interested in accessing investigational drugs may search for open trials via ClinicalTrials.gov. Enrollment is subject to strict eligibility criteria, and patients should discuss potential participation with their treating oncologist.

How do doctors identify PTEN deficiency?

PTEN status is typically identified through molecular testing, such as immunohistochemistry (IHC) or next-generation sequencing (NGS) of tumor tissue. If you are interested in biomarker testing, ask your doctor about the availability of genomic profiling for your specific cancer diagnosis.

Is capivasertib the same as other AKT inhibitors?

No. While other AKT inhibitors have been studied in various oncology settings, each drug has a unique chemical structure and toxicity profile. Capivasertib is a specific, potent inhibitor of all three isoforms of AKT.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.